Gsk (GLAXF) Income from Non-Controlling Interests (2009 - 2026)

Gsk's Income from Non-Controlling Interests history runs 18 years deep, the most recent figure standing at $2.5 billion for Q1 2026.

• In Q1 2026, Income from Non-Controlling Interests rose 11.09% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $15.9 billion (up 105.6% YoY), while the FY2025 annual figure was $755.5 million, up 57.19% from the prior year.
• Income from Non-Controlling Interests was $2.5 billion for Q1 2026 at Gsk, down from $8.4 billion in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $8.4 billion in Q4 2025 to a low of $23.6 million in Q3 2022.
• Historically, Income from Non-Controlling Interests has averaged $2.1 billion across 5 years, with a median of $2.0 billion in 2023.
• The sharpest annual moves came in 2023 and 2024: Income from Non-Controlling Interests soared 8143.59% in 2023, then slumped 95.65% in 2024.
• A 5-year view of Income from Non-Controlling Interests shows it stood at $369.5 million in 2022, then jumped by 1034.08% to $4.2 billion in 2023, then decreased by 9.61% to $3.8 billion in 2024, then jumped by 120.86% to $8.4 billion in 2025, then plunged by 70.36% to $2.5 billion in 2026.
• The last three Income from Non-Controlling Interests figures came in at $2.5 billion (Q1 2026), $8.4 billion (Q4 2025), and $2.9 billion (Q3 2025), per Business Quant data.